ZEUS System vs Tempus ECG-AF
AI Verdict
Choose ZEUS System if…
Choose ZEUS System if you require long-term, continuous cardiac monitoring to detect and characterize intermittent or asymptomatic arrhythmias over an extended period. This tool is ideal for patients needing up to 14 days of continuous ECG data analysis from wearable biosensors to capture elusive cardiac events and aid in early arrhythmia detection and management.
View ZEUS System →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based algorithm provides valuable risk stratification from a single 12-lead ECG, guiding earlier follow-up and preventative strategies for eligible patients without pre-existing AF.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ZEUS System | Tempus ECG-AF |
|---|---|---|
| Pricing | Not disclosed | Contact vendor |
| Deployment | Cloud-based (AWS EC2 platform), no on-premise hardware. | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ZEUS SystemTool A, the ZEUS System, leverages a cloud-based platform and integrates with wearable biosensors for continuous monitoring, potentially simplifying long-term data collection for patients and streamlining initial report generation for physicians. Its HL7-based EHR integration further enhances its ease of use within existing healthcare IT environments.
Clinical Value
ZEUS SystemThe ZEUS System (Tool A) offers direct diagnostic and characterization capabilities for existing arrhythmias through continuous, long-term ECG monitoring, providing immediate actionable insights for patient management. Tempus ECG-AF (Tool B) focuses on predicting the risk of future AF, which is valuable for preventative care but less direct for current diagnostic needs.
Pricing & Value
Tempus ECG-AFTempus ECG-AF (Tool B) clearly outlines CMS reimbursement codes (CPT 0764T and CPT 0765T) and a specific Medicare rate, providing transparency and a clear path for financial viability and adoption within healthcare systems. The ZEUS System (Tool A) does not disclose its pricing, making it difficult to assess its economic value proposition.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements (BAAs). While Tool A's cloud-native deployment might offer simplified IT infrastructure, Tool B's compatibility with widely used 12-lead ECG systems also ensures smooth integration into existing clinical workflows.
Innovation
ZEUS SystemThe ZEUS System (Tool A) integrates AI with long-term continuous wearable monitoring for direct arrhythmia detection and characterization, representing a significant innovation in extending the diagnostic window and improving the detection of intermittent conditions. While Tempus ECG-AF (Tool B)'s predictive algorithm for future AF risk is also innovative, Tool A's approach fundamentally changes how cardiac data is collected and analyzed over an extended period.
Support & Docs
TieBoth iRhythm Technologies and Tempus AI are established companies in the healthcare AI space, and it is expected that they provide comprehensive support and documentation for their FDA-cleared products. However, specific details regarding the depth, accessibility, or responsiveness of their support and documentation are not publicly available for either tool.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ZEUS System | Tempus ECG-AF |
|---|---|---|
| Name | ZEUS System | Tempus ECG-AF |
| Company | iRhythm Technologies | Tempus AI, Inc. |
| Description | The ZEUS System by iRhythm Technologies is an AI-powered software that analyzes ECG data from wearable biosensors for long-term continuous cardiac monitoring, aiding in the detection and characterization of arrhythmias like Atrial Fibrillation. | Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Key Feature: ECG Analysis Type | Continuous ECG monitoring (up to 14 days) from wearable biosensors | AI-based algorithm for 12-lead ECG analysis |
| Key Feature: Target Condition | Detection and characterization of Atrial Fibrillation (AFib) and other arrhythmias | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months |
| Key Feature: Patient Population | Support for symptomatic and asymptomatic cardiac events | Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery |
Videos
Demos, reviews, and walkthroughs featuring ZEUS System and Tempus ECG-AF.
Frequently Asked Questions
More Comparisons
More matchups featuring ZEUS System or Tempus ECG-AF
Backers
Who funded each tool's parent company.